<DOC>
	<DOCNO>NCT00074230</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's dendritic cell antigen may make body build immune response kill tumor cell . PURPOSE : Phase I/II trial study effectiveness vaccine therapy use autologous dendritic cell antigens treat patient stage IV cutaneous melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage IV Cutaneous Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability vaccination autologous monocyte-derived dendritic cell ( DC ) transfected RNAs encode Melan-A , MAGE-3 , survivin antigen patient stage IV cutaneous melanoma . - Determine whether tumor antigen-specific T-cell response induce patient treated vaccine . - Determine whether simultaneous load DC keyhole limpet hemocyanin ( KLH ) significantly enhance induction Melan-A , MAGE-3 , survivin antigen patient . Secondary - Determine clinical antitumor activity ( e.g. , objective tumor response , time tumor progression , progression-free interval , overall survival ) patient treat vaccine . OUTLINE : This open-label , nonrandomized study . - Phase I : Beginning 9-11 day vaccination , patient undergo leukapheresis collection peripheral blood mononuclear cell ( PBMCs ) . PBMCs process generation dendritic cell ( DC ) use vaccination . PBMCs transfected RNAs encode Melan-A , MAGE-3 , survivin antigen . DC pulse keyhole limpet hemocyanin ( KLH ) patient . Patients receive antigen-pulsed ( without KLH ) DC vaccination subcutaneously ( SC ) day 1 , 15 , 43 , 71 absence disease progression unacceptable toxicity . Patients stable respond disease may proceed phase II portion study . - Phase II : Patients undergo leukapheresis phase I day 102 , 354 , 690 . Patients receive 6 additional booster vaccination SC phase I day 127 , 185 , 269 , 356 , 521 , 692 . Patients follow 10 year . PROJECTED ACCRUAL : A total 8-30 patient accrue study within 6-12 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cutaneous* melanoma Stage IV Incurable surgical resection Progressive disease least 1 standard chemotherapy chemoimmunotherapy regimen ( e.g. , dacarbazine cisplatin monotherapy ) Unidimensionally bidimensionally measurable disease physical examination ( e.g. , cutaneous metastasis ) and/or noninvasive radiological procedure No active CNS metastasis CT scan MRI Previously treat ( e.g. , excision single metastasis ) CNS metastases allow provided sign active CNS metastasis NOTE : *Metastatic melanoma unidentified primary tumor allow provided ocular melanoma definitely exclude origin skin likely PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy At least 4 month Hematopoietic WBC great 2,500/mm^3 Neutrophil count great 1,000/mm^3 Lymphocyte count great 700/mm^3 Platelet count great 75,000/mm^3 Hemoglobin great 9 g/dL No bleeding disorder Hepatic Bilirubin le 2.0 mg/dL No evidence hepatitis B C infection Renal Creatinine le 2.5 mg/dL Cardiovascular No clinically significant heart disease Pulmonary No respiratory disease Immunologic HIV1 HIV2 negative HTLV1 negative No active systemic infection No immunodeficiency disease No active autoimmune disease ( e.g. , lupus erythematosus , autoimmune thyroiditis uveitis , multiple sclerosis , inflammatory bowel disease ) Vitiligo allow Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 4 week study participation Stable medical condition No major serious illness No contraindication leukapheresis No organic brain syndrome significant psychiatric abnormality would preclude study participation followup No active malignant neoplasm PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior immunotherapy No concurrent immunotherapy 2 week study participation Chemotherapy More 4 week since prior systemic chemotherapy ( 6 week nitrosoureas [ e.g. , fotemustine ] ) No concurrent chemotherapy 2 week study participation Endocrine therapy No concurrent corticosteroid 2 week study participation Radiotherapy More 2 week since prior radiotherapy No prior radiotherapy spleen Concurrent palliative radiotherapy select metastasis ( e.g. , due pain local complication compression ) allow Surgery Recovered prior surgery No prior splenectomy No prior organ allografts Concurrent surgical therapy select metastasis ( e.g. , due pain local complication compression ) allow Selected accessible metastasis may remove tumor infiltrate lymphocyte assay immunomonitoring investigation ( e.g. , expression tumor antigens HLA molecule ) Other No concurrent investigational drug paramedical substance 2 week study participation No concurrent participation another clinical trial Concurrent palliative medication allow ( e.g. , acetaminophen , indomethacin , opiate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>